Saturday, October 24, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

GLP-1tirzepatidesemaglutideprediabetesprimary care

Chart review of 40 rural prediabetes patients finds A1c normalized on incretins

Semaglutide or tirzepatide use over three to 24 months was also tied to lower BMI, blood pressure, LDL and triglycerides in a single clinic.

MH
By Maren Holt · Senior Reporter, GLP-1

The wire

  1. 01A retrospective chart review of 40 rural adults with prediabetes and overweight or obesity treated three to 24 months found significant improvements in A1c, BMI, systolic and diastolic blood pressure, LDL and triglycerides (p < .001).
  2. 02Authors argue nurse practitioners in rural primary care can use incretin therapy for early prediabetes management, a setting where trial evidence is thin.
  3. 03All participants reached normoglycemic A1c, but the design is observational, single-site and small, with potential confounding the authors say warrants cautious interpretation.

From the source

A Retrospective Chart Review of Tirzepatide and Semaglutide Use in Prediabetes Management and Cardiometabolic Outcomes in a Rural Primary Care Setting

Journal of doctoral nursing practice · 2026 Oct 15 · Holland AB, Andrabi MS, Appel SJ et al.

Read at pubmed.ncbi.nlm.nih.gov
PeptiPrescribed peptides from $99/moSee all →